As you might know, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) just kicked off its latest first-quarter results with some very strong numbers. It looks like a positive result overall, with revenues of US$69m beating forecasts by 5.7%. Statutory losses of US$0.45 per share were 5.7% smaller than the analysts expected, likely helped along by the higher revenues. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.NasdaqGM:PRCT Earnings and Revenue Growth April 28th 2025

Taking into account the latest results, the consensus forecast from PROCEPT BioRobotics' ten analysts is for revenues of US$324.3m in 2025. This reflects a major 30% improvement in revenue compared to the last 12 months. Losses are forecast to narrow 8.5% to US$1.51 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$321.7m and losses of US$1.49 per share in 2025.

See our latest analysis for PROCEPT BioRobotics

As a result, it's unexpected to see that the consensus price target fell 15% to US$77.00, with the analysts seemingly becoming more concerned about ongoing losses, despite making no major changes to their forecasts. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values PROCEPT BioRobotics at US$91.00 per share, while the most bearish prices it at US$60.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await PROCEPT BioRobotics shareholders.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that PROCEPT BioRobotics' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 42% growth on an annualised basis. This is compared to a historical growth rate of 54% over the past three years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.0% per year. So it's pretty clear that, while PROCEPT BioRobotics' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of PROCEPT BioRobotics' future valuation.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple PROCEPT BioRobotics analysts - going out to 2027, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk.  We've identified 2 warning signs  with PROCEPT BioRobotics , and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments